// App-Quantinova.ai

DXT35 : Feasibility of Classic MS Assessing Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets in the Phase 3 Trials

Researchers

Presenter

  • Mark S Freedman

Principal Investigators

  • Alexey N Boyko

  • Jorge Correale

  • Gavin Giovannoni

  • Thomas Leist

  • Xavier Montalban

  • Kottil Rammohan

  • Bassem Yamout

  • Pedro Testi

  • Kristin Gabriel

Medical Centers

  • Division of Neurology, University of Toronto

  • Vall d'Hebron University Hospital...

  • Thomas Jefferson University, PA

  • University of Milan

  • Neurology, American University of Beirut Medical Center

  • THe University of Ottawa and Ottawa Hospital Research Institute

  • Queen Mary University, London, UK

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00213135

  • NCT00641537

  • NCT00725985

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved